Astrocytes in ALS

Astrocytes in ALS
**Category**	Glial Cells
**Location**	Motor cortex, spinal cord anterior horn, brainstem
**Cell Type**	Reactive astrocytes (A1/A2 phenotype)
**Markers**	GFAP, AQP4, S100B, ALDH1L1
**Disease**	Amyotrophic Lateral Sclerosis
Marker	Change
GFAP	↑ 3-5x
C3	↑ 10-50x
S100B	↑
EAAT2	↓ 50-80%
Approach	Status
**Riluzole**	Approved
**Edaravone**	Approved
**Celecoxib**	Trial
**CNTF delivery**	Trial
**GDNF delivery**	Trial
Model	Features
**SOD1G93A mice**	Standard ALS model, rapid progression
**SOD1G37R mice**	Slower progression, later onset
**C9orf72 mice**	Models hexanucleotide expansion
**Astrocyte-specific SOD1**	Demonstrates non-cell autonomy
**iPSC-derived astrocytes**	Patient-specific research

Introduction

Astrocytes In Als is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.

Overview

Normal Astrocyte Functions

Homeostatic Support

• Potassium buffering: Kir4.1 channel-mediated K+ uptake maintains extracellular K+ homeostasis

• Water balance: AQP4 channels regulate water flux at the blood-brain barrier

• pH regulation: Carbonic anhydrase activity maintains acid-base balance

Metabolic Support

• Lactate shuttle: Provides metabolic substrates to neurons

• Glycogen storage: Energy reserve for neural activity

• Tricarboxylic acid cycle: Supports oxidative phosphorylation in neurons

Neurotransmitter Regulation

• Glutamate uptake: EAAT1 (GLAST) and EAAT2 (GLT-1) transporters clear extracellular glutamate

• GABA recycling: GABA transaminase metabolism

• Ammonia detoxification: Glutamine synthesis

Synaptic Function

• Synapse formation: Promote excitatory and inhibitory synapse formation

• Perisynaptic astrocytic processes: Modulate synaptic transmission

• Tripartite synapse: Integral component of synaptic architecture

Astrocyte Dysfunction in ALS

Reactive Astrocyte Phenotype

A1 Neurotoxic Phenotype

ALS astrocytes acquire an A1-like reactive phenotype similar to that observed in Alzheimer’s disease and Parkinson’s disease: ^{1Human embryonic stem cell-derived motor neurons are sensitive to ALS-causing gene mutations2008 · PMID 19041780Open reference}

• Upregulated genes: GFAP, S100B, C3, Serpina3n, complement components

• Downregulated genes: Glutamate transporters, Kir4.1, AQP4

• Function: Gain of toxic functions, loss of supportive functions

Phenotypic Markers

Mechanisms of Motor Neuron Toxicity

1. Glutamate Excitotoxicity

• EAAT2/GLT-1 downregulation: 50-80% reduction in ALS spinal cord

• Reduced glutamate clearance: Extracellular glutamate accumulates

• AMPA/Kainate receptor overactivation: Ca²⁺ influx, excitotoxic death

• Therapeutic target: Riluzole (glutamate modulator)

2. Mitochondrial Dysfunction

• Reduced oxidative phosphorylation: ATP depletion

• Increased ROS production: Oxidative stress

• Impaired calcium handling: Vulnerability to excitotoxicity

• Mutant SOD1 effects: Direct mitochondrial damage

3. Neuroinflammation

• Pro-inflammatory cytokines: IL-1β, IL-6, TNF-α

• Chemokine secretion: CCL2, CXCL10 recruitment of immune cells

• Complement activation: C1q, C3-mediated synapse elimination

• NF-κB activation: Persistent inflammatory state

4. Metabolic Failure

• Lactate production defects: Energy starvation of motor neurons

• Impaired glycogenolysis: Loss of energy reserves

• Reduced pyruvate carrier: Altered glucose metabolism

5. Loss of Trophic Support

• Reduced BDNF secretion: Survival factor deficiency

• Impaired GDNF signaling: Motor neuron protection loss

• Defective Notch signaling: Developmental dysregulation

Genetic Forms of ALS

SOD1 Mutations

• Over 150 mutations: A4V, G93A, G37R, etc.

• Astrocyte-specific effects: Mutant SOD1 expressed in astrocytes

• Non-cell autonomous toxicity: Astrocyte-to-motor neuron spread

C9orf72 Expansion

• Hexanucleotide repeat expansion: Most common genetic cause

• Dipeptide repeat proteins (DPRs): Toxic to astrocytes

• RNA foci formation: Sequestration of RNA-binding proteins

TDP-43 Pathology

• Cytoplasmic inclusions: Found in 97% of ALS cases

• Astrocyte involvement: TDP-43 aggregates in astrocytes

• RNA splicing defects: Global dysregulation

FUS Mutations

• Fused in Sarcoma (FUS): RNA-binding protein mutations

• Astrocyte nuclear loss: Cytoplasmic mislocalization

• Impaired RNA metabolism: Widespread splicing defects

Therapeutic Implications

Astrocyte-Targeted Therapies

Emerging Strategies

• Astrocyte reprogramming: Converting to protective phenotype

• iPSC-derived astrocytes: Patient-specific disease modeling

• Gene therapy: Targeting astrocyte-specific pathways

• MicroRNA therapy: Modulating astrocyte function

Animal Models

Cross-Links

• Amyotrophic Lateral Sclerosis - Main disease page

• Motor Neurons - Motor neuron biology

• GFAP (Glial Fibrillary Acidic Protein) - Astrocyte marker

• [Neuroinflammation](/mechanisms/neuroinflamm- Mitochondrial Dysfunctions

• Mitochondrial Dysfunction Energy failure

• Excitotoxicity - Glutamate toxicity

• SOD1 Gene - Superoxide dismutase

Background

The study of Astrocytes In Als has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

• Alzheimer’s Disease

• Amyloid Hypothesis

• Tau Pathology

• Parkinson’s Disease

• α-Synuclein

External Links

• PubMed - Biomedical literature

• Alzheimer’s Disease Neuroimaging Initiative - Research data

• Allen Brain Atlas - Brain gene expression data

External Links

• ALS - NIH

• Astrocytes in Disease - Scholar